Fujian Haixi Pharmaceuticals Co., Ltd.

This study tests a new drug (C019199) combined with an immunotherapy (sintilimab) in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 155 adults with v…